Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weak dollar hits Bayer healthcare sales:

This article was originally published in Clinica

Executive Summary

First-half sales of Bayer's healthcare division, which includes diagnostics, rose 2% on year-earlier levels to DM 5,600 million ($3,916 million). Turnover suffered badly from the weak dollar, the company comments. Group sales climbed 4.5% to DM 23,184 million. Products from the Diagnostics business group are among those due to be produced in Beijing by Bayer's new Chinese pharmaceutical joint venture. An agreement to set up the venture was signed in July with Beijing Economic Technological Investment Development Corporation (BETIDC), which holds a 5% stake.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT092846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel